ATRA Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

03

Price $9.48

Market Cap (MRQ) $90M

P/E (TTM) -5.5

EPS (TTM) $-1.73

Revenue (TTM) $6M

ROE (TTM) 46.3%

52W Range $4–$19

ATRA Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

04

range

bars

Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.

Stock splits 1

Ex-date	Split	Type
June 20, 2024	1-for-25	Reverse

About Atara Biotherapeutics, Inc. - Common Stock Company overview from Wikipedia

05 · wikidata

Wikidata ↗

sectorHealthcare industryBiotechnology employees10 countryUS

10-Year Performance Revenue, net income, margins and EPS trends

06

Revenue$121M

2022-12-31 → 2025-12-31

EPS$2.57

2020-12-31 → 2025-12-31

Free Cash Flow$-51M

2016-12-31 → 2025-12-31

Net margin-269.4%

2023-12-31 → 2025-12-31

Valuation & Ratios 07–12

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Metric	ATRA	5Y avg	Peer Median	Verdict
P/E (TTM)	-5.55Y avg ≈-27.9	≈-27.9	·	·
P/S (TTM)	14.55Y avg ≈71.2	≈71.2	70.6	Undervalued
P/B (MRQ)	-2.45Y avg ≈34.7	≈34.7	·	·
Price / FCF	-1.45Y avg ≈-39.1	≈-39.1	·	·
Price / Cash Flow	-1.45Y avg ≈-40.7	≈-40.7	·	·
Price / Tangible Book	7.25Y avg ≈68.3	≈68.3	·	·

Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.

Profitability Gross, operating and net margins; ROE, ROA, ROIC

Metric	ATRA	5Y avg	Peer Median	Verdict
Operating Margin (TTM)	-229.7%5Y avg ≈-1084.8%	≈-1084.8%	-2434.3%	Top tier
EBITDA Margin	29.7%5Y avg ≈-1084.8%	≈-1084.8%	-2434.3%	Top tier
Pretax Margin (TTM)	-269.0%5Y avg ≈-1086.6%	≈-1086.6%	-3416.0%	Top tier
Net Profit Margin (TTM)	-269.4%5Y avg ≈-1086.7%	≈-1086.7%	-2336.0%	Top tier
ROA (TTM)	-57.6%5Y avg ≈-46.4%	≈-46.4%	-30.1%	Top tier
ROE (TTM)	46.3%5Y avg ≈21.8%	≈21.8%	-50.0%	Weak
ROIC	-93.0%5Y avg ≈-14.5%	≈-14.5%	-52.7%	Weak

Financial Health Debt, liquidity, solvency — balance sheet strength

Metric	ATRA	5Y avg	Peer Median	Verdict
Current Ratio (MRQ)	2.05Y avg ≈1.9	≈1.9	5.3	Low liquidity
Quick Ratio (MRQ)	1.55Y avg ≈1.7	≈1.7	3.8	Low liquidity
Interest Coverage	9.55Y avg ≈-20.3	≈-20.3	·	·

Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR

Metric	5Y trend	ATRA	5Y avg	Peer Median	Verdict
Revenue YoY		-6.3%5Y avg ≈437.1%	≈437.1%	·	·
Revenue CAGR 3Y		23.8%	·	·	·

Per Share Metrics EPS, book value per share, cash flow per share, dividend per share

Metric	ATRA	5Y avg	Peer Median	Verdict
EPS (Diluted)	$2.575Y avg ≈$-15.98	≈$-15.98	·	·
Revenue / Share	$9.505Y avg ≈$8.93	≈$8.93	·	·
Cash Flow / Share	$-4.015Y avg ≈$-4.41	≈$-4.41	·	·
Cash / Share	$1.165Y avg ≈$1.56	≈$1.56	·	·

Capital Efficiency Asset turnover, inventory turnover, receivables turnover

Metric	ATRA	5Y avg	Peer Median	Verdict
Asset Turnover	1.95Y avg ≈0.9	≈0.9	0.0	Top tier
Receivables Turnover	88.35Y avg ≈31.9	≈31.9	·	·
Revenue / Employee	≈$12.1M	·	·	·

value · ≈ 5Y avg · industry median · verdict relative to median

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

14

Avg Surprise 76.0%

Next Report Nov 10, 2026

Period	Report	EPS Actual	EPS Est	Surprise
June 30, 2026	Aug 10, 2026	$-0.32	$-0.32	0.40%
March 31, 2026	May 13, 2026	$-0.29	$-0.41	29.8%
Dec. 31, 2025		$-0.25	$-0.17	-43.0%
Sept. 30, 2025		$-0.32	$-0.88	63.5%
June 30, 2025		$0.19	$-0.47	140.5%
March 31, 2025		$3.50	$-2.02	273.3%
Dec. 31, 2024		$-1.19	$-3.65	67.4%

Full Fundamentals All metrics by year — income statement, balance sheet, cash flow

15

Income Statement 16

Metric	2025	2024	2023	2022
Revenue	$121M	$129M	$9M	$64M
R&D Expense	$37M	$151M	$225M	$273M
SG&A Expense	$26M	$40M	$51M	$72M
Operating Expenses	$85M	$212M	$285M	$344M
Operating Income	$36M	$-83M	$-276M	$-281M
Interest Expense	$4M	$5M	$5M	$373.0K
Interest Income	$683.0K	$2M	$5M	$3M
Other Non-op	$-34.0K	$528.0K	$-246.0K	$-700.0K
Pretax Income	$33M	$-85M	$-276M	$-228M
Income Tax	$31.0K	$-12.0K	$15.0K	$12.0K
Net Income	$33M	$-85M	$-276M	$-228M
EPS (Basic)	$2.61	$-11.41	$-65.19	$-2.24
EPS (Diluted)	$2.57	$-11.41	$-65.19	$-2.24
Shares (Basic)	12,544,000	7,488,000	4,236,000	101,990,000
Shares (Diluted)	12,718,000	7,488,000	4,236,000	101,990,000
EBITDA	$36M	$-83M	$-276M	$-281M

Balance Sheet 23

Metric	2025	2024	2023	2022
Cash & Equivalents	$8M	$25M	$26M	$93M
Short-term Investments	$0	$17M	$26M	$150M
Receivables	$1M	$1M	$34M	$40M
Inventory	$0	$11M	$10M	$2M
Other Current Assets	$2M	$10M	$6M	$10M
Current Assets	$12M	$65M	$102M	$295M
PP&E (Net)	$73.0K	$1M	$4M	$6M
PP&E (Gross)	$286.0K	$19M	$20M	$19M
Accum. Depreciation	$213.0K	$17M	$16M	$12M
Other Non-current Assets	$886.0K	$3M	$5M	$7M
Total Assets	$20M	$109M	$166M	$376M
Accounts Payable	$127.0K	$4M	$4M	$7M
Accrued Liabilities	$2M	$6M	$19M	$7M
Current Liabilities	$15M	$135M	$142M	$79M
Capital Leases	$9M	$30M	$46M	$58M
Other Non-current Liabilities	$2M	$3M	$5M	$6M
Total Liabilities	$59M	$206M	$265M	$250M
Common Stock	$1.0K	$1.0K	$0	$10.0K
Retained Earnings	$-2.02B	$-2.05B	$-1.97B	$-1.69B
AOCI	$1.0K	$8.0K	$-204.0K	$-2M
Stockholders' Equity	$-39M	$-97M	$99M	$127M
Liabilities + Equity	$20M	$109M	$166M	$376M
Shares Outstanding	7,324,000	5,859,000	4,258,000	95,927,000

Cash Flow 13

Metric	2025	2024	2023	2022
D&A	$2M	$5M	$5M	$6M
Stock-based Comp	$10M	$27M	$45M	$54M
Deferred Tax	$0	$0	·	·
Restructuring	$13M	$5M	$7M	$6M
Operating Cash Flow	$-51M	$-69M	$-193M	$-270M
CapEx	$0	$246.0K	$1M	$4M
Investing Cash Flow	$18M	$9M	$124M	$203M
Stock Issued	$1M	$9M	$2M	$22M
Net Stock Activity	$1M	$9M	$2M	$22M
Financing Cash Flow	$16M	$59M	$2M	$53M
Taxes Paid	$190.0K	$24.0K	$2.0K	$19.0K
Free Cash Flow	$-51M	$-69M	$-194M	$-275M
Levered FCF	$-55M	$-74M	$-199M	·

Profitability 7

Metric	2025	2024	2023	2022
Operating Margin	29.7%	-64.7%	-3219.5%	·
Net Margin	27.1%	-66.2%	-3220.9%	·
Pretax Margin	27.1%	-66.2%	-3220.7%	·
EBITDA Margin	29.7%	-64.7%	-3219.5%	·
ROA	50.5%	-62.2%	-101.9%	-54.1%
ROE	-88.9%	90.9%	368.0%	-145.5%
ROIC	-93.0%	85.8%	278.2%	-221.5%

Liquidity & Solvency 3

Metric	2025	2024	2023	2022
Current Ratio	0.8	0.5	0.7	3.7
Quick Ratio	0.7	0.3	0.6	3.6
Interest Coverage	9.5	-18.1	-52.2	·

Efficiency 2

Metric	Trend	2025	2024	2023	2022
Asset Turnover		1.9	0.9	0.0	·
Receivables Turnover		88.3	7.2	0.2	·

Per Share 5

Metric	2025	2024	2023	2022
Book Value / Share	$-5.26	$-16.60	$-0.93	$1.32
Revenue / Share	$9.50	$17.22	$0.08	·
Cash Flow / Share	$-4.01	$-9.18	$-1.82	$-2.65
Cash / Share	$1.16	$4.27	$0.24	$0.97
EPS (TTM)	$2.57	$-11.41	$-65.19	$-2.24

Growth Rates 2

Metric	Trend	2025	2024	2023	2022
Revenue YoY		-6.3%	1404.0%	-86.5%	·
Revenue CAGR 3Y		23.8%	·	·	·

Valuation (TTM) 10

Metric	2025	2024	2023	2022
Revenue TTM	$121M	$129M	$9M	$64M
Net Income TTM	$33M	$-85M	$-276M	$-228M
Market Cap	$132M	$78M	$1.37B	$7.87B
P/E	7.0	-1.2	-0.2	-36.6
P/S	1.1	0.6	159.2	123.7
P/B	-3.4	-0.8	-13.8	62.1
P / Tangible Book	·	·	13.8	62.1
P / Cash Flow	-2.6	-1.1	-7.1	-29.1
P / FCF	-2.6	-1.1	-7.0	-28.6
Earnings Yield	14.2%	-85.7%	-508.3%	-2.7%

Income Statement 16

Metric	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Revenue	$630.0K	$516.0K	$2M	$3M	$18M	$98M	$33M	$40M	$29M	$27M	$4M	$2M	$957.0K	$1M	$221.0K	$4M
R&D Expense	$1M	$164.0K	$-223.0K	$3M	$7M	$27M	$29M	$44M	$33M	$46M	$50M	$57M	$56M	$62M	$63M	$70M
SG&A Expense	$4M	$4M	$4M	$4M	$7M	$11M	$9M	$10M	$9M	$11M	$11M	$12M	$13M	$14M	$13M	$19M
Operating Expenses	$5M	$4M	$4M	$7M	$14M	$59M	$45M	$62M	$47M	$59M	$64M	$72M	$72M	$76M	$76M	$89M
Operating Income	$-5M	$-3M	$-3M	$-4M	$3M	$39M	$-12M	$-22M	$-18M	$-31M	$-60M	$-70M	$-71M	$-75M	$-76M	$-85M
Interest Expense	$191.0K	$830.0K	$894.0K	$909.0K	$972.0K	$1M	$1M	$1M	$1M	$1M	$1M	$1M	$1M	$1M	$117.0K	$123.0K
Interest Income	$78.0K	$54.0K	$100.0K	$204.0K	$143.0K	$236.0K	$597.0K	$459.0K	$450.0K	$604.0K	$711.0K	$1M	$2M	$2M	$1M	$973.0K
Other Non-op	$0	$0	$-49.0K	$4.0K	$22.0K	$-11.0K	$-89.0K	$555.0K	$-6.0K	$68.0K	$-12.0K	$-27.0K	$-10.0K	$-197.0K	$-68.0K	$-309.0K
Pretax Income	$-5M	$-4M	$-3M	$-4M	$2M	$38M	$-13M	$-22M	$-19M	$-32M	$-60M	$-70M	$-71M	$-75M	$-75M	$-84M
Income Tax	$1.0K	$0	$0	$28.0K	$3.0K	$0	$-19.0K	$-17.0K	$0	$24.0K	$11.0K	$-19.0K	$1.0K	$22.0K	$2.0K	$10.0K
Net Income	$-5M	$-4M	$-3M	$-4M	$2M	$38M	$-13M	$-22M	$-19M	$-32M	$-60M	$-70M	$-71M	$-75M	$-75M	$-84M
EPS (Basic)	$-0.32	$-0.29	$-0.80	$-0.32	$0.20	$3.53	$0.27	$-2.93	$-3.10	$-5.65	$-31.16	$-16.40	$-16.91	$-0.72	$-0.73	$-0.82
EPS (Diluted)	$-0.32	$-0.29	$-0.80	$-0.32	$0.19	$3.50	$0.27	$-2.93	$-3.10	$-5.65	$-31.16	$-16.40	$-16.91	$-0.72	$-0.73	$-0.82
Shares (Basic)	15,033,000	14,081,000	·	13,564,000	12,197,000	10,764,000	·	7,466,000	6,143,000	5,623,000	·	4,256,000	4,204,000	103,969,000	·	102,423,000
Shares (Diluted)	15,033,000	14,081,000	·	13,564,000	12,310,000	10,851,000	·	7,466,000	6,143,000	5,623,000	·	4,256,000	4,204,000	103,969,000	·	102,423,000
EBITDA	·	$-3M	·	$-4M	$3M	$39M	·	$-22M	$-18M	$-31M	·	$-70M	$-71M	$-75M	·	$-85M

Balance Sheet 24

Metric	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Cash & Equivalents	$3M	$8M	$8M	$6M	$17M	$14M	$25M	$46M	$31M	$35M	$26M	$65M	$46M	$49M	$93M	$65M
Short-term Investments	$7M	·	$0	$8M	$5M	$0	$17M	$21M	$4M	$11M	$26M	$38M	$108M	$157M	$150M	$200M
Receivables	$318.0K	$0	$1M	$2M	$0	$9M	$1M	$1M	$2M	$36M	$34M	$163.0K	$507.0K	$397.0K	$40M	$249.0K
Inventory	·	·	$0	$0	$0	$0	$11M	$14M	$19M	$16M	$10M	$7M	$8M	$5M	$2M	·
Prepaid Expense	·	·	·	·	·	·	·	·	·	·	·	·	·	·	·	$16M
Other Current Assets	$3M	$4M	$2M	$3M	$2M	$4M	$10M	$9M	$6M	$8M	$6M	$9M	$10M	$13M	$10M	·
Current Assets	$14M	$12M	$12M	$18M	$25M	$27M	$65M	$92M	$62M	$106M	$102M	$119M	$172M	$224M	$295M	$283M
PP&E (Net)	$41.0K	$55.0K	$73.0K	$147.0K	$176.0K	$285.0K	$1M	$2M	$2M	$3M	$4M	$5M	$5M	$6M	$6M	$7M
PP&E (Gross)	·	·	$286.0K	$551.0K	$551.0K	$2M	$19M	$20M	$20M	$20M	$20M	$20M	$20M	$19M	$19M	$20M
Accum. Depreciation	·	·	$213.0K	$404.0K	$375.0K	$2M	$17M	$18M	$17M	$17M	$16M	$15M	$14M	$13M	$12M	$12M
Other Non-current Assets	$765.0K	$890.0K	$886.0K	$881.0K	$927.0K	$3M	$3M	$3M	$4M	$4M	$5M	$6M	$7M	$7M	$7M	$7M
Total Assets	$21M	$20M	$20M	$30M	$37M	$62M	$109M	$143M	$117M	$165M	$166M	$189M	$246M	$302M	$376M	$368M
Accounts Payable	$824.0K	$637.0K	$127.0K	$318.0K	$2M	$1M	$4M	$2M	$5M	$3M	$4M	$7M	$4M	$5M	$7M	$11M
Accrued Liabilities	$2M	$2M	$2M	$3M	$5M	$9M	$6M	$8M	$11M	$18M	$19M	$8M	$11M	$7M	$7M	·
Current Liabilities	$7M	$6M	$15M	$18M	$15M	$48M	$135M	$156M	$148M	$181M	$142M	$79M	$75M	$68M	$79M	$72M
Capital Leases	$9M	$9M	$9M	$15M	$15M	$27M	$30M	$35M	$39M	$42M	$46M	$49M	$52M	$55M	$58M	$61M
Other Non-current Liabilities	$2M	$2M	$2M	$2M	$2M	$3M	$3M	$4M	$4M	$4M	$5M	$5M	$5M	$5M	$6M	$6M
Total Liabilities	$58M	$57M	$59M	$67M	$72M	$117M	$206M	$233M	$228M	$264M	$265M	$240M	$239M	$237M	$250M	$181M
Common Stock	$1.0K	$1.0K	$1.0K	$1.0K	$1.0K	$1.0K	$1.0K	$1.0K	$0	$12.0K	$0	$10.0K	$10.0K	$10.0K	$10.0K	$9.0K
Retained Earnings	$-2.03B	$-2.03B	$-2.02B	$-2.02B	$-2.01B	$-2.02B	$-2.05B	$-2.04B	$-2.02B	$-2.00B	$-1.97B	$-1.91B	$-1.84B	$-1.77B	$-1.69B	$-1.62B
AOCI	$-2.0K	$0	$1.0K	$2.0K	$0	$0	$8.0K	$22.0K	$-14.0K	$-55.0K	$-204.0K	$-571.0K	$-933.0K	$-1M	$-2M	$-3M
Stockholders' Equity	$-37M	$-37M	$-39M	$-37M	$-35M	$-55M	$-97M	$-91M	$-111M	$-98M	$-99M	$-51M	$7M	$65M	$127M	$187M
Liabilities + Equity	$21M	$20M	$20M	$30M	$37M	$62M	$109M	$143M	$117M	$165M	$166M	$189M	$246M	$302M	$376M	$368M
Shares Outstanding	9,443,000	8,512,000	7,324,000	7,210,000	6,978,000	5,924,000	5,859,000	5,740,000	4,904,000	120,325,000	4,258,000	101,922,000	101,102,000	96,538,000	95,927,000	94,879,000

Cash Flow 12

Metric	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
D&A	$14.0K	$29.0K	$49.0K	$36.0K	$236.0K	$2M	$1M	$1M	$1M	$1M	$1M	$1M	$1M	$1M	$1M	$1M
Stock-based Comp	$394.0K	$749.0K	$2M	$1M	$3M	$4M	$6M	$6M	$6M	$8M	$10M	$11M	$13M	$12M	$11M	$14M
Restructuring	$767.0K	$0	$1M	$27.0K	$2M	$10M	$0	$0	$356.0K	$5M	$7M	$0	$0	$45.0K	$74.0K	$6M
Operating Cash Flow	$-3M	$-3M	$-6M	$-10M	$-7M	$-28M	$-24M	$-4M	$-11M	$-30M	$-50M	$-51M	$-53M	$-38M	$-57M	$-65M
CapEx	·	·	$0	$0	$0	$0	$90.0K	$0	$29.0K	$127.0K	$44.0K	$281.0K	$499.0K	$399.0K	$37.0K	$132.0K
Investing Cash Flow	$-7M	$0	$8M	$-2M	$-5M	$17M	$3M	$-17M	$7M	$15M	$10M	$70M	$49M	$-6M	$51M	$60M
Stock Issued	$5M	$3M	$-25.0K	$1M	$0	$0	$0	$0	$-26.0K	$9M	$2M	$0	$-50.0K	$640.0K	$1M	$0
Net Stock Activity	·	$3M	·	·	·	$0	·	·	·	$9M	·	·	·	$640.0K	·	·
Financing Cash Flow	$5M	$3M	$-3.0K	$1M	$15M	$-250.0K	$-328.0K	$36M	$-324.0K	$24M	$2M	$-208.0K	$471.0K	$235.0K	$32M	$-214.0K
Taxes Paid	·	·	$159.0K	$28.0K	$3.0K	$0	$0	$0	$0	$24.0K	$0	$0	$1.0K	$1.0K	$0	$0
Free Cash Flow	·	·	·	·	·	$-28M	·	·	·	$-30M	·	·	·	$-39M	·	·
Levered FCF	·	·	·	·	·	$-29M	·	·	·	$-31M	·	·	·	$-40M	·	·

Profitability 7

Metric	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Operating Margin	·	-652.9%	·	-103.5%	18.2%	39.5%	·	-54.1%	-63.7%	-114.2%	·	-3255.9%	-7462.3%	-6118.9%	·	·
Net Margin	·	-803.3%	·	-124.6%	13.6%	38.7%	·	-54.5%	-66.5%	-116.1%	·	-3264.6%	-7430.3%	-6098.8%	·	·
Pretax Margin	·	-803.3%	·	-123.8%	13.6%	38.7%	·	-54.6%	-66.5%	-116.0%	·	-3265.5%	-7430.2%	-6097.0%	·	·
EBITDA Margin	·	-652.9%	·	-103.5%	18.2%	39.5%	·	-54.1%	-63.7%	-114.2%	·	-3255.9%	-7462.3%	-6118.9%	·	·
ROA	·	-10.1%	·	-5.0%	3.1%	33.4%	·	-13.2%	-10.5%	-13.6%	·	-25.1%	-20.8%	-21.4%	·	-20.5%
ROE	·	9.0%	·	6.8%	-3.3%	-49.6%	·	31.0%	36.8%	190.4%	·	-102.4%	-53.7%	-51.7%	·	-33.8%
ROIC	·	9.0%	·	9.8%	-9.1%	-70.5%	·	24.0%	16.4%	31.8%	·	136.9%	-958.1%	-115.5%	·	-45.2%

Liquidity & Solvency 3

Metric	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Current Ratio	·	2.2	·	1.0	1.7	0.6	·	0.6	0.4	0.6	·	1.5	2.3	3.3	·	3.9
Quick Ratio	·	1.5	·	0.9	1.5	0.5	·	0.4	0.3	0.5	·	1.3	2.1	3.0	·	3.7
Interest Coverage	·	-4.1	·	-3.9	3.3	38.2	·	-18.4	-14.4	-27.1	·	-49.9	-51.8	-56.2	·	·

Efficiency 2

Metric	Trend	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Asset Turnover		·	0.0	·	0.0	0.2	0.9	·	0.2	0.2	0.1	·	0.0	0.0	0.0	·	·
Receivables Turnover		·	0.1	·	2.1	14.5	4.4	·	53.7	19.6	1.5	·	10.4	1.7	2.3	·	·

Per Share 5

Metric	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Book Value / Share	·	$-4.38	·	$-5.08	$-5.02	$-9.30	·	$-15.77	$-22.61	$-0.82	·	$-0.50	$0.07	$0.67	·	$1.97
Revenue / Share	·	$0.04	·	$0.25	$1.43	$9.05	·	$5.38	$4.66	$0.19	·	$0.02	$0.01	$0.01	·	·
Cash Flow / Share	·	$-0.22	·	·	·	$-2.59	·	·	·	$-0.21	·	·	·	$-0.37	·	·
Cash / Share	·	$0.98	·	$0.80	$2.42	$2.34	·	$8.09	$6.39	$0.29	·	$0.64	$0.45	$0.50	·	$0.69
EPS (TTM)	$-0.74	$-1.22	·	$3.64	$1.03	$-2.26	·	$-42.84	$-56.31	$-70.12	·	$-34.76	$-19.18	$-2.09	·	$-2.47

Valuation (TTM) 9

Metric	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Revenue TTM	$22M	$23M	·	$152M	$189M	$200M	·	$100M	$62M	$35M	·	$5M	$7M	$57M	·	·
Net Income TTM	$-11M	$-9M	·	$23M	$6M	$-16M	·	$-133M	$-181M	$-233M	·	$-290M	$-305M	$-215M	·	$-247M
Market Cap	·	$40M	·	$103M	$54M	$35M	·	$47M	$42M	$2.09B	·	$3.77B	$4.07B	$7.00B	·	$8.97B
P/E	-15.5	-3.9	·	3.9	7.5	-2.6	·	-0.2	-0.2	-0.2	·	-1.1	-2.1	-34.7	·	-38.3
P/S	·	1.7	·	0.7	0.3	0.2	·	0.5	0.7	60.2	·	830.3	592.9	121.8	·	·
P/B	·	-1.1	·	-2.8	-1.5	-0.6	·	-0.5	-0.4	-21.2	·	-74.2	545.9	107.7	·	47.9
P / Tangible Book	·	·	·	·	·	·	·	·	·	·	·	·	545.9	107.7	·	47.9
P / Cash Flow	·	-13.1	·	·	·	-1.3	·	·	·	-70.5	·	·	·	-182.1	·	·
Earnings Yield	-6.5%	-25.8%	·	25.4%	13.3%	-38.0%	·	-526.9%	-662.5%	-404.2%	·	-94.0%	-47.6%	-2.9%	·	-2.6%

Most recent period on the left · null values shown as ·

Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years

16

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue	$121M	$129M	$9M	$64M	·
Operating Margin %	29.7%	-64.7%	-3219.5%	·	·
Net Income	$33M	$-85M	$-276M	$-228M	$-340M
Diluted EPS	$2.57	$-11.41	$-65.19	$-2.24	$-3.63

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Current Ratio	0.8	0.5	0.7	3.7	3.6
Quick Ratio	0.7	0.3	0.6	3.6	3.5

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Free Cash Flow	$-51M	$-69M	$-194M	$-275M	$-231M

Institutional owners (13F) 38 filers · $54.9M total · As of June 30, 2026

17

Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.

Holders 38

Value held $54.9M

New positions 4

Exited positions 1

Institutional activity — Q2 2026 vs prior quarter

New positions	Exited positions	Increased	Decreased	Net shares change
4 (-3 vs prior Q)	1 (-13 vs prior Q)	12 (+2 vs prior Q)	8 (+5 vs prior Q)	+1.9M

Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.

Institution	Value	Shares	% of tracked 13F	Type
EcoR1 Capital, LLC	$17,816,960	1,552,000	32.43%	Shares
ADAGE CAPITAL PARTNERS GP, L.L.C.	$9,758,000	850,000	17.76%	Shares
Point72 Asset Management, L.P.	$7,895,003	687,718	14.37%	Shares
Redmile Group, LLC	$5,070,727	441,701	9.23%	Shares
VANGUARD GROUP INC	$4,087,255	225,940	7.44%	Shares
VANGUARD CAPITAL MANAGEMENT LLC	$2,836,100	247,047	5.16%	Shares
MACKENZIE FINANCIAL CORP	$2,677,699	233,249	4.87%	Shares
BlackRock, Inc.	$969,544	84,455	1.76%	Shares
GEODE CAPITAL MANAGEMENT, LLC	$862,924	75,128	1.57%	Shares
STALEY CAPITAL ADVISERS INC	$574,000	50,000	1.04%	Shares
VANGUARD FIDUCIARY TRUST CO	$494,053	43,036	0.90%	Shares
JANE STREET GROUP, LLC	$348,360	30,345	0.63%	Shares
STATE STREET CORP	$303,680	26,453	0.55%	Shares
NORTHERN TRUST CORP	$190,465	16,591	0.35%	Shares
FMR LLC	$186,412	16,238	0.34%	Shares
XTX Topco Ltd	$175,678	15,303	0.32%	Shares
BRIDGEWAY CAPITAL MANAGEMENT, LLC	$160,720	14,000	0.29%	Shares
MILLENNIUM MANAGEMENT LLC	$145,566	12,680	0.26%	Shares
CITADEL ADVISORS LLC	$116,625	10,159	0.21%	Shares
MORGAN STANLEY	$105,368	9,178	0.19%	Shares
ROYAL BANK OF CANADA	$55,000	4,743	0.10%	Shares
UBS Group AG	$45,679	3,979	0.08%	Shares
Vanguard Global Advisers, LLC	$16,715	1,456	0.03%	Shares
SBI Securities Co., Ltd.	$16,118	1,404	0.03%	Shares
JONES FINANCIAL COMPANIES LLLP	$8,440	803	0.02%	Shares
Caitong International Asset Management Co., Ltd	$3,570	311	0.01%	Shares
BARCLAYS PLC	$3,490	304	0.01%	Shares
Banque Transatlantique SA	$3,096	176	0.01%	Shares
WELLS FARGO & COMPANY/MN	$2,881	251	0.01%	Shares
JPMORGAN CHASE & CO	$2,413	216	0.00%	Shares
Raiffeisen Bank International AG	$2,296	200	0.00%	Call option
CITIGROUP INC	$1,114	97	0.00%	Shares
BNP PARIBAS FINANCIAL MARKETS	$528	46	0.00%	Shares
ACADIAN ASSET MANAGEMENT LLC	$444	38,845	0.00%	Shares
PlanVest Financial, Inc	$321	28	0.00%	Shares
KERR FINANCIAL PLANNING Corp	$276	24	0.00%	Shares
OSAIC HOLDINGS, INC.	$114	10	0.00%	Shares
Rockefeller Capital Management L.P.	$92	8	0.00%	Shares

Activists & 5%+ owners 3 positions

18

Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.

Filer	Filed	Stake	Status	Purpose	Filing
Redmile Group, LLC, Green Jeremy, Redmile Biopharma Investments II, L.P., Redmile Strategic Long Only Trading Sub, Ltd. ×4 filings	July 24, 2026	9.90%	Amendment	·	SEC
Panacea Innovation Limited, Panacea Venture Healthcare Fund II, L.P., Panacea Venture Healthcare Fund II GP Company, Ltd., Panacea Opportunity Fund I, L.P., Panacea Opportunity Fund I GP Company, Ltd., James Huang ×4 filings	May 11, 2026	16.10%	Amendment	·	SEC
Adiumentum Capital Fund I LP, Adiumentum Capital Fund I GP LLC, Gregory A. Ciongoli ×3 filings	May 16, 2025	19.99%	Amendment	·	SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Company insiders 35 insiders · 19 officers · 16 directors

19

Insider	Role	Last activity	Shares owned	Buys 12m	Sells 12m	Net 12m
Anhco Nguyen	President and CEO	Aug. 17, 2026 S	132,775	0	8	$-142,448
Isaac E. Ciechanover	Chief Executive Officer	May 30, 2019 S	290,687	0	0	$0
Utpal Koppikar	Chief Financial Officer	March 2, 2023 S	181,978	0	0	$0
John Mcgrath	EVP & Chief Financial Officer	March 20, 2018 S	88,762	0	0	$0
Yanina Grant-Huerta	Chief Accounting Officer	May 18, 2026 S	49,636	0	8	$-56,523
Jill Henrich	EVP, Chief Regulatory Officer	March 3, 2025 S	18,679	0	0	$0
Amar Murugan	EVP, Chief Legal Officer	Aug. 16, 2024 S	26,827	0	0	$0
Manher Joshi	EVP, Chief Medical Officer	Nov. 16, 2023 S	171,284	0	0	$0
Charlene A. Banard	EVP, Chief Technical Officer	May 16, 2023 S	276,010	0	0	$0
Jakob Dupont	EVP, Head of R&D	March 2, 2023 S	290,794	0	0	$0
Kristin Yarema	Chief Commercial Officer	March 1, 2022 A	171,415	0	0	$0
Joe Newell	Chief Operations Officer	Nov. 16, 2021 S	113,097	0	0	$0
Dietmar Berger	Global Head of R&D	May 7, 2019 F	85,678	0	0	$0
Mina Kim	Senior VP & General Counsel	April 9, 2019 F	66,389	0	0	$0
Derrell Porter	SVP, Head of Global Commercial	March 26, 2019 A	31,688	0	0	$0
Christopher Haqq	EVP, R&D & Chief Scientific Of	Feb. 15, 2019 S	271,943	0	0	$0
Gad Soffer	EVP & Chief Strategy Officer	Sept. 22, 2018 F	243,966	0	0	$0
Mitchall G. Clark	EVP & Chief R & QA Officer	May 18, 2018 S	107,972	0	0	$0
Heather D Turner	Former EVP, GC & Sec.	Feb. 9, 2018 S	69,494	0	0	$0
Brian N Cherry	Director	Sept. 4, 2026 P	166,486	1	0	$999,994
Gregory A. Ciongoli	Director	June 9, 2026 A	12,000	0	0	$0
Matthew K Fust	Director	June 9, 2026 A	30,188	0	0	$0
William K Heiden	Director	June 9, 2026 A	34,188	0	0	$0
Ameet Mallik	Director	June 10, 2025 A	16,928	0	0	$0
Maria Grazia Roncarolo	Director	June 10, 2025 A	17,368	0	0	$0
Pascal Touchon	Director	June 10, 2025 A	77,955	0	0	$0
Carol Giltner Gallagher	Director	June 10, 2025 A	33,012	0	0	$0
Eric Dobmeier	Director	Nov. 10, 2023 P	563,325	0	0	$0
Beth C Seidenberg	Director	May 31, 2023 A	115,689	0	0	$0
Roy D. Baynes	Director	June 23, 2022 A	43,500	0	0	$0
Ronald C Renaud JR	Director	June 23, 2022 A	31,500	0	0	$0
Joel S Marcus	Director	March 15, 2019 S	888,355	0	0	$0
Eckard Weber	Director	Jan. 16, 2015 A	·	0	0	$0
EcoR1 Capital, LLC	10% owner	May 7, 2026 P	1,552,000	1	0	$4,744,255
Eric J Hyllengren	·	March 31, 2025 D	56,231	0	0	$0

Insiders from SEC Form 3/4/5 filings; net = open-market P/S only

ETF ownership Held by 4 ETFs

20

Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.

Fund	Weight	Units	As of	Source
IWC · iShares Trust	0.01%	18,824 SH	Sept. 11, 2026	Daily
VXF · VANGUARD INDEX FUNDS	0.00%	82,758 SH	Aug. 19, 2026	Daily
VTI · VANGUARD INDEX FUNDS	0.00%	158,646 SH	Aug. 19, 2026	Daily
DFAS · Dimensional ETF Trust	0.00%	135 NS	July 31, 2026	N-PORT

ATRA Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

21

rating · 10 analysts BUY

Median target $13.00 +37.1%

2 20.0% Strong Buy

6 60.0% Buy

2 20.0% Hold

0 0.0% Sell

0 0.0% Strong Sell

12-Month Price Target

3 analysts · 2026-10-02

Mean target $13.67 +44.2%

← Below all targets Current price $9.48

Low$10.00 Mean$13.67 High$18.00

Peer comparison (GICS sub-industry) Key metrics vs sector peers

22

FY basis, prices as of each company's last fiscal year-end close.

Ticker	Market Cap	P/E	Rev YoY	Net Margin	ROE	Gross Margin
ATRA	$132M	7.0	-6.3%	27.1%	-88.9%	·
CNXU	·	·	·	·	·	·
RLYB	$4M	-0.4	34.9%	-1046.4%	-17.3%	·
MNOV	$64M	-5.5	·	-2928.8%	-27.1%	·
ICCC	·	-51.2	4.3%	·	·	·
ACRV	$76M	-1.2	·	·	-61.0%	·
SERA	·	-4.4	5.2%	-39417.3%	-39.0%	·
GRML	·	·	·	·	-104.9%	·
GANX	$135M	-5.3	-60.6%	·	-181.1%	·

My Metrics Your personal watchlist — selected rows from Full Fundamentals

26

Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.

Your selection is saved and follows you across all tickers.

ATRA Atara Biotherapeutics, Inc. - Common Stock